I lost 8st on fat jabs but felt severely hungover & was constantly on the loo – but I'm happier than ever being skinny
A MOTHER has revealed that she lost over eight stone whilst using Mounjaro, but has been accused of 'cheating' her weight loss.
Not only this, but Kelsey, the mum from Glasgow, has constantly found herself on the loo and has been battling with feeling severely hungover, despite not having a drop of alcohol.
4
A mother has opened up on her Mounjaro weight loss and her battle with diarrhoea and exhaustion
Credit: tiktok.com/@kelseymounjaroandme
4
Kelsey also clapped back at those who accuse her of "cheating" her weight loss
Credit: tiktok.com/@kelseymounjaroandme
4
Mounjaro is typically used to treat type 2 diabetes
Credit: Getty
The content creator, who has lost 8 stone 13lbs since August 2024, got candid on the unfortunate fat jab side effects, but despite this, claimed that she is 'happier than ever' being slim.
Posting on social media, alongside a picture of Kelsey shortly after giving birth to her baby, she confirmed that as a result of taking Mounjaro, which is regarded by some as the King Kong of weight loss jabs, she has been accused of 'cheating' her weight loss.
But just seconds later, the brunette beauty showed off her newly slimmed down frame as she wore a cropped co-ord, held up a drink and beamed: 'I'll forever cheers to 'cheating'.'
Eager to clap back at those who hail Mounjaro 'the easy way out', Kelsey explained: 'You don't know the years I spent trapped in a cycle of diets that didn't work.
'You don't know the pain of battling a body that felt like it was working against me because of PCOS.'
Not only this, but Kelsey also claimed that prior to using Mounjaro, she was exhausted and faced 'quiet moments' where she 'nearly gave up.'
She then claimed that she is 'not 'stealing' from anyone', and instead, is 'reclaiming' her health and 'showing up' for herself in a way she never thought she could.
Now, Kelsey claimed that her 'mum tum' is 'barely noticeable'.
Not only this, but she stressed that Mounjaro 'changed' her life and now she feels 'happier than ever.'
Sun GP Dr Zoe Williams claimed that Mounjaro, which could soon be rolled out on the NHS, can save the lives of people with 'life-threatening levels of obesity'.
Weight Loss Jabs - Pros vs Cons
But despite this, the NHS warned: 'Never take an anti-obesity medicine if it has not been prescribed to you.
"These types of medicines may not be safe for you and can cause serious side effects.'
I have been up since 5:30am feeling sick, really, really sick - back and forward to the toilet
Kelsey
In another clip, Kelsey got candid on her side effects after increasing her Mounjaro dose to 12.5mg.
The mother explained that she had initially been 'so lucky' when it came to experiencing Mounjaro side effects, but after starting on the 12.5mg dose, things all changed.
She admitted: 'Oh my goodness, I feel severely hungover, I feel like I've got the worst hangover.
'I feel so, so tired. I have been up since 5:30am feeling sick, really, really sick - back and forward to the toilet.'
Kelsey explained that not only has she been dealing with diarrhoea and stomach cramps, but she also claimed that her body, particularly her feet, are 'so swollen.'
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
According to WebMD, swelling in the feet, ankles or legs can happen when using Mounjaro, especially if you are dehydrated, which can happen if you aren't drinking enough water or are dealing with diarrhoea.
The pros also acknowledged that diarrhoea, as well as stomach pain, are just two of the 'most common side effects of Mounjaro'.
Social media users react
The TikTok clip, which was posted under the username @kelseymounjaroandme, has clearly left many open-mouthed, as it has quickly amassed 175,600 views.
Despite her side effects, social media users were stunned by Kelsey's incredible weight loss and many eagerly raced to the comments to express this.
One person said: 'Oh my you look incredible!!'
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Another added: 'Wow!! Incredible transformation.'
Meanwhile, a third commented: 'You're stunning!'
Fatal consequences
In addition to diarrhoea and stomach cramps, those debating whether to begin using Mounjaro should know that the jabs can have fatal consequences.
The injections are licensed for patients with type 2 diabetes and are administered every seven days.
4
They are also available to assist those who are clinically obese (with a Body Mass Index of 30 or over).
The drugs can be prescribed by a practitioner - such as a doctor, nurse or a pharmacist-independent prescriber.
But increasingly, we are seeing more and more people buying them through online pharmacies, without sufficient checks.
Not only this, but figures from the Medicines and Healthcare products Regulatory Agency revealed that fat jabs had been linked to 82 deaths across the UK.
Following the death of a man from Burton upon Trent, Staffs, who died after taking Mounjaro, his family are now calling for a probe into the jab's "potential to kill."
Unlock even more award-winning articles as The Sun launches brand new membership programme - Sun Club
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
21 minutes ago
- BBC News
Breakthrough Alzheimer's drugs too pricey to be offered on NHS
Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the medicines are the first to slow the disease, which may give people extra time living National Institute for Health and Care Excellence (NICE) concluded they were a poor use of taxpayers' money and said funding them could lead to other services being say it is a disappointment, but dementia experts have also supported the decision. The two drugs, donanemab and lecanemab, both help the body clear a gungy protein that builds up in the brains of people with Alzheimer's medicines do not reverse or even stop the disease, rather brain power is lost more slowly with trials of these drugs were celebrated as a scientific triumph as they showed, for the first time, it was possible to change the course of Alzheimer' since then a row has developed over the cost of the drugs and how meaningful the benefit is. The official price in the US is £20,000-£25,000 per patient per year. What the NHS would pay is 70,000 people in England with mild dementia would have been eligible, potentially putting the bill in the region of £1.5bn a year for the drugs resources, including regularly infusing the drugs directly into spinal fluid and frequent brain scans to manage dangerous side effects, would also massively ramp up the cost. The benefit of the drugs is also debated. They potentially delay the transition from mild to moderate dementia by four-to-six months. That could mean more time without needing daily care, driving, being present for significant family events and Prof Rob Howard, from University College London, said real-world benefits "were too small to be noticeable". In trials of lecanemab, patients were better off by 0.45 points, on an 18-point scale ranging from healthy to severe he said the cost would "have been close to the cost of a nurse's salary for each treated patient".The decision not to fund the drugs is not a surprise. The first assessment last year concluded they were not Knight, director of medicines evaluation at NICE, acknowledged the latest news would be "disappointing" but said the benefits were "modest" at best while requiring "substantial resources"."If they were approved they could displace other essential treatments and services that deliver significant benefits to patients," she said. NICE said its appraisal had factored in potential savings in the cost of providing care, but the drugs were still deemed decisions apply to the NHS in England, but are normally adopted by Wales and Northern Ireland too. Scotland has its own method for approving pharmaceutical companies have three weeks to raise concerns about how the review was performed, otherwise the decision becomes final on 23 pharmaceutical companies involved, Eisai for lecanemab and Eli Lilly for donanemab, say they will appeal against the decision. Nick Burgin, from Eisai said the NHS "is not ready" for the challenge of tackling Alzheimer's and flaws in the process meant their drug would have been rejected "even if Eisai provided lecanemab to the NHS for free".Eli Lilly, the company behind donanemab, has already expressed its disappointment. "If the system can't deliver scientific firsts to NHS patients, it is broken," said Chris Stokes, Eli Lilly's president and general manager of UK and Northern Europe. Is this a distraction or a disappointment? The sentiment was echoed by both the Alzheimer's charities. Prof Fiona Carragher, from the Alzheimer's Society said "the science is flying but the system is failing" and it was "highly disappointing" the drugs were not available on the Evans-Newton, the chief executive at Alzheimer's Research UK, said the result was "painful" and patients will miss out on this and future innovations "not because science is failing, but because the system is".However, others say NICE has made the right call. Tom Dening, professor of dementia research at the University of Nottingham, said he was "in complete support" as the benefits of the drugs were "minimal" and a "distraction" from the real issues in dementia."[Namely the] unglamorous challenge of providing people with dementia and their families with activities, care and support that we already know are beneficial for their mental and physical health," he Atticus Hainsworth, from St George's, University of London, said: "NICE is simply doing its job."Beyond lecanemab and donenamab there are 138 dementia medicines being tested in 182 trials around the Tara Spires-Jones, director of the centre for discovery brain sciences at the University of Edinburgh, said: "There is hope for safer, more effective treatments on the horizon."
Rhyl Journal
22 minutes ago
- Rhyl Journal
What is rabies and how to recognise symptoms of infection?
Human cases of rabies are very rare in the UK, but it poses a risk to travellers visiting regions where the disease remains prevalent. While the risk is still small, rabies is more common in parts of Asia, Africa, Central America and South America. Here's all you need to know about the infection, including how to recognise symptoms and how to avoid it. If you're travelling to a country where rabies is present, it's worth knowing how to reduce your risk - read our blog post for more info. 🔗 According to the NHS website, rabies is spread by mammals, such as dogs, bats, raccoons and foxes. You can get rabies if you're bitten or scratched by an infected animal. Additionally, it can be passed on if an infected animal licks your eyes, nose or mouth, or you have a wound that's licked by an infected animal. Rabies symptoms usually take between three to 12 weeks to appear, but they can also occur within a few days or take several months or years. Symptoms of the infection include: Once symptoms develop in an infected person after they have been exposed, it is almost always fatal. The UK Health Security Agency (UKHSA) says you need to take a number of immediate steps if you believe you have been in contact with a rabies-infected animal. You should wash the wound with plenty of soap and water for several minutes to reduce the risk of infection. Additionally, seek local medical attention without delay, as treating it sooner will be more effective. They add: "Contact your GP on return to the UK, even if you received post-exposure treatment abroad or the exposure happened several weeks ago. "You may need to continue a course of rabies vaccines. If you have a record of any treatment given, remember to bring this with you." According to the NHS website, the level of protection varies, but a full course should last one or two years. People who are travelling to areas with a risk of rabies more than a year after their course of vaccines can have a single booster dose. If you're travelling to a region where there is a chance of rabies, you need to take preventative measures. The UKHSA recommends consulting a travel health professional before your trip. Recommended reading: Person dies in Yorkshire from rabies after contact with a stray dog in Morocco How long do colds last and how can you cure them quickly? Urgent Mounjaro and Ozempic warning for anyone planning a holiday They can determine if pre-exposure vaccination is recommended based on your destination and planned activities. The UKHSA adds: "Vaccination is particularly important if you'll be staying for over a month, engaging in outdoor activities, or travelling to areas with limited access to medical care." It is also advised to avoid contact with animals as much as possible when travelling.
Daily Mail
an hour ago
- Daily Mail
Alzheimer's drugs rejected for NHS because the benefits 'are too small to justify the cost', watchdog says
Two drugs to treat Alzheimer's disease have been rejected for use on the NHS because their benefits are 'too small' to justify their cost, the health spending watchdog has said. The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers. Charities described the decision as 'disappointing' and a 'painful setback' for patients, while the firms Lilly, which makes donanemab, and Eisai, which makes lecanemab, said they would appeal. Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. Publishing its final draft guidance, Nice said the treatments have been shown to delay progression from mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Professor Fiona Carragher, Alzheimer's Society's chief policy and research Officer, said the decision was 'disappointing'. The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them Professor Fiona Carragher, Alzheimer's Society She said: 'There is no doubt that today's decision is a setback for people with Alzheimer's disease. 'It is highly disappointing that we are in a situation where treatments that slow the progression of the condition are not available on the NHS. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia. 'The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them. 'The science is flying but the system is failing.' While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them Helen Knight, director of medicines evaluation at Nice She said the Government must now commit to 'the long-term investment needed to fundamentally change dementia diagnosis so that we are ready for new treatments', including bringing in earlier diagnosis and access to specialist diagnostic tests. She added: 'We are heading towards a future where disease-slowing treatments reduce the devastating impact of dementia, and we cannot afford to delay preparing the NHS for them.' Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said: 'This rejection is a painful setback for people affected by Alzheimer's – but sadly not a surprising one. 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges. 'People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately. 'This decision sends a troubling signal to the life sciences sector – undermining confidence in the UK as a home for research, innovation and clinical trials. That risks lasting damage to both patients and the economy. People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately Hilary Evans-Newton, Alzheimer's Research UK 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments. 'With over 30 Alzheimer's drugs now in late-stage trials globally, momentum is building – and more will enter regulatory systems in the years ahead. 'Without intervention from Government, people with Alzheimer's will continue to miss out — not because science is failing, but because the system is.' Helen Knight, director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them. 'The committee accepted that any slowing of the disease getting worse would be meaningful for people with mild cognitive impairment or mild dementia caused by Alzheimer's disease and their carers because it could mean more time socialising, driving and being independent, so needing less help day-to-day from family members. 'But the committee concluded the small benefits to patients shown in the clinical trials and the lack of long-term evidence of effectiveness balanced with the substantial resources the NHS would need to commit to the treatments would be too great and could displace other essential treatments and services that deliver substantial benefits to patients. 'We have done everything we possibly can to try and achieve a positive outcome in our assessments of these treatments, including providing an additional opportunity for evidence to be submitted. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation.' Drug firms and registered patient groups now have until July 8 to appeal against the decision. In clinical trials, donanemab, which is given via a drip, has been shown to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab – also administered via drip – has been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. However, side-effects of the drugs can be serious, including brain bleeds and risk of death. A reformulation of lecanemab is being developed so it can be administered subcutaneously under the skin. Nice could then review the drug in this form. There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost effective Dr Jeremy Isaacs, NHS England Lilly said it would appeal the Nice decision on the grounds it was unreasonable based on the evidence submitted. Chris Stokes, president and general manager of UK and Northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost effective.'
